IMV - IMV STOCK NEWS

IMV Inc. announced that it received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share, based on the closing bid price for the 30 consecutive business days from February 14 to March 28, 2023. The company has a compliance period of 180 days to regain compliance, ending on September 25, 2023. If compliance is not achieved, IMV may face potential delisting but may also be eligible for an additional 180-day cure period. The notification does not affect the current trading status of IMV's shares on Nasdaq or the TSX.

IMV Inc. (NASDAQ: IMV; TSX: IMV) has announced the immediate resignation of Dr. Shermaine Tilley from its Board of Directors due to policy changes at CTI Life Sciences Fund, where she serves as Managing Partner. Dr. Tilley has been a board member since 2016, following CTI's initial investment in IMV. IMV has appointed Brittany Davison, the Chief Accounting Officer, as an interim board member while searching for a Canadian replacement. Dr. Tilley's contributions during her seven years with the company were acknowledged by Chairman Michael Bailey, emphasizing her significant industry experience.

IMV Inc. reported significant updates on its clinical trials and financial position. The company is advancing MVP-S in two global Phase 2B trials for relapsed/refractory DLBCL and platinum-resistant ovarian cancer. Multiple complete clinical responses were observed in the ongoing VITALIZE study, with enrollment expected to finish by Q2 2023. Additionally, IMV completed a $9M financing and retained Stonegate Healthcare Partners to explore strategic alternatives. Financially, IMV had cash and cash equivalents of $21.2M at the end of 2022, with a net loss of $38M for the year.

IMV Inc. (NASDAQ: IMV; TSX: IMV) announced a conference call on March 16, 2023, at 8:00 a.m. ET to discuss its 2022 fourth quarter and fiscal year-end financial results. The company is focused on developing immune-educating therapies for various cancers using its DPX platform, particularly the lead candidate MVP-S, which targets the survivin cancer antigen. MVP-S is undergoing clinical evaluation for multiple cancer types, including Diffuse Large B Cell Lymphoma and ovarian cancer. Investors and analysts can register for the call online or access a recorded version via IMV's website, available for 30 days post-event.

IMV Inc. has announced positive preliminary data from the VITALIZE Phase 2B trial of its lead product, maveropepimut-S (MVP-S), combined with pembrolizumab for treating relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL). Among 6 evaluable patients, 3 achieved confirmed complete responses, with no adverse safety signals reported. The trial aims to recruit up to 102 patients, assessing the treatment's efficacy. CEO Andrew Hall highlighted the significance of these results, especially given the challenging patient population. The Overall Response Rate (ORR) will be reported later when all data is available.

IMV Inc. presented initial data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023. The company anticipates preliminary clinical response data from the AVALON Phase 2b trial in H2 2023. IMV recently secured a strengthened financial position by completing a $9M financing, with cash and equivalents reaching $21.1M by December 31, 2022. Additionally, Shabnam Kazmi has been appointed to the Board of Directors following Julia P. Gregory's retirement.